{"id":22177,"date":"2023-12-16T21:12:50","date_gmt":"2023-12-16T21:12:50","guid":{"rendered":"https:\/\/dupmecp2.eu\/huidagene-une-technologie-crispr-cas13-prometteuse-venue-de-chine-shanghai\/"},"modified":"2023-12-20T18:46:25","modified_gmt":"2023-12-20T18:46:25","slug":"huidagene-una-prometedora-tecnologia-crispr-cas13-de-china-shanghai","status":"publish","type":"post","link":"https:\/\/dupmecp2.eu\/es\/huidagene-una-prometedora-tecnologia-crispr-cas13-de-china-shanghai\/","title":{"rendered":"Huidagene: una prometedora tecnolog\u00eda CRISPR-CAS13 de China (Shanghai)"},"content":{"rendered":"<p>Huidagene Therapeutics es una empresa biotecnol\u00f3gica con sede en Shanghai y Nueva Jersey, centrada en el descubrimiento, ingenier\u00eda y desarrollo de nuevos f\u00e1rmacos basados en la tecnolog\u00eda CRISPR. La empresa se centra en trastornos musculares, oft\u00e1lmicos y neurol\u00f3gicos.<\/p>\n\n\n\n<p>Huidagene ha desarrollado el HG204, un vector de virus adenoasociado (AAV) que introduce en las c\u00e9lulas un innovador complejo CRISPR-Cas13. Especialmente dise\u00f1ado para el s\u00edndrome de duplicaci\u00f3n del gen MECP2, <strong>El HG204 pretende regular la sobreproducci\u00f3n de la prote\u00edna MeCP2 induciendo la degradaci\u00f3n del exceso de ARN de MECP2.<\/strong> Este innovador candidato a f\u00e1rmaco tiene el potencial de curar el s\u00edndrome de duplicaci\u00f3n del gen MECP2 con una sola administraci\u00f3n.<\/p>\n\n\n\n<div style=\"height:25px\" aria-hidden=\"true\" class=\"wp-block-spacer\"><\/div>\n\n\n\n<p>Nuestra organizaci\u00f3n ha mantenido fruct\u00edferas conversaciones con la direcci\u00f3n de Huidagene para saber m\u00e1s sobre esta innovadora tecnolog\u00eda y lo que representa para el futuro. <strong>Los estudios precl\u00ednicos realizados con HG204 en un modelo de rat\u00f3n humanizado han demostrado una reducci\u00f3n significativa de la prote\u00edna MeCP2 y una inversi\u00f3n de los s\u00edntomas.<\/strong> Adem\u00e1s de que estos resultados son alentadores, se trata tambi\u00e9n de la segunda prueba de la reversibilidad de los s\u00edntomas del s\u00edndrome tras la regulaci\u00f3n de los niveles de prote\u00edna MECP2 (como ya hab\u00eda demostrado anteriormente la administraci\u00f3n de ASO por el Prof. H. Zoghbi).<\/p>\n\n\n\n<div style=\"height:25px\" aria-hidden=\"true\" class=\"wp-block-spacer\"><\/div>\n\n\n\n<p><strong>En la actualidad, Huidagene est\u00e1 finalizando los estudios precl\u00ednicos sobre el HG204 y preparando un ensayo cl\u00ednico para pacientes en China, cuyo inicio est\u00e1 previsto para el verano de 2024. <\/strong>Si este estudio resulta concluyente, Huidagene tiene previsto realizar ensayos cl\u00ednicos en otros pa\u00edses, como Estados Unidos y Europa, en 2025-2026.<\/p>\n\n\n\n<p><br>El 31 de octubre, la Food and Drug Administration (FDA) estadounidense concedi\u00f3 a HG204 las designaciones de enfermedad pedi\u00e1trica rara y medicamento hu\u00e9rfano. Esta designaci\u00f3n reglamentaria es un primer paso hacia un ensayo cl\u00ednico fuera de China, y permitir\u00e1 una revisi\u00f3n acelerada del expediente cuando se registre el medicamento. Aunque la noticia es totalmente inesperada, aporta una esperanza adicional a la comunidad.<\/p>\n\n\n\n<p>Nuestro equipo se mantendr\u00e1 en contacto con Huidagene y mantendr\u00e1 informada a nuestra comunidad de cualquier novedad.<\/p>\n\n\n\n<figure class=\"wp-block-image size-large is-resized\"><img decoding=\"async\" data-src=\"https:\/\/dupmecp2.eu\/wp-content\/uploads\/2023\/12\/Huidagene_Pipeline_2023_white-edited.png\" alt=\"\" class=\"wp-image-22144 lazyload\" style=\"--smush-placeholder-width: 1920px; --smush-placeholder-aspect-ratio: 1920\/1080;width:840px;height:auto\" src=\"data:image\/svg+xml;base64,PHN2ZyB3aWR0aD0iMSIgaGVpZ2h0PSIxIiB4bWxucz0iaHR0cDovL3d3dy53My5vcmcvMjAwMC9zdmciPjwvc3ZnPg==\" \/><\/figure>\n\n\n\n<div class=\"wp-block-buttons is-layout-flex wp-block-buttons-is-layout-flex\">\n<div class=\"wp-block-button\"><a class=\"wp-block-button__link has-background wp-element-button\" href=\"https:\/\/www.huidagene.com\/new\/news\/48\" style=\"border-radius:16px;background-color:#f7a13c\" target=\"_blank\" rel=\"noreferrer noopener\">A la revista de prensa<\/a><\/div>\n<\/div>","protected":false},"excerpt":{"rendered":"<p>Huidagene Therapeutics est une soci\u00e9t\u00e9 de biotechnologie bas\u00e9e \u00e0 Shanghai et dans le New Jersey, qui se concentre sur la d\u00e9couverte, l&rsquo;ing\u00e9nierie et le d\u00e9veloppement de nouveaux m\u00e9dicaments bas\u00e9s sur [&hellip;]<\/p>","protected":false},"author":1,"featured_media":22151,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[7],"tags":[],"class_list":["post-22177","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-actualite"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v25.8 - https:\/\/yoast.com\/wordpress\/plugins\/seo\/ -->\n<title>Huidagene : Une technologie CRISPR-CAS13 prometteuse venue de Chine (Shanghai) - DupMECP2<\/title>\n<meta name=\"description\" content=\"Une nouvelle perspective potentielle pour le traitement du syndrome de duplication MECP2 avec le CRIPSR-Cas13 de Huidagene. Le candidat-m\u00e9dicament HG204 a d\u00e9montr\u00e9 une r\u00e9duction significative de la prot\u00e9ine MeCP2 et la r\u00e9versibilit\u00e9 des sympt\u00f4mes.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/dupmecp2.eu\/es\/huidagene-una-prometedora-tecnologia-crispr-cas13-de-china-shanghai\/\" \/>\n<meta property=\"og:locale\" content=\"es_ES\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Huidagene : Une technologie CRISPR-CAS13 prometteuse venue de Chine (Shanghai) - DupMECP2\" \/>\n<meta property=\"og:description\" content=\"Une nouvelle perspective potentielle pour le traitement du syndrome de duplication MECP2 avec le CRIPSR-Cas13 de Huidagene. Le candidat-m\u00e9dicament HG204 a d\u00e9montr\u00e9 une r\u00e9duction significative de la prot\u00e9ine MeCP2 et la r\u00e9versibilit\u00e9 des sympt\u00f4mes.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/dupmecp2.eu\/es\/huidagene-una-prometedora-tecnologia-crispr-cas13-de-china-shanghai\/\" \/>\n<meta property=\"og:site_name\" content=\"DupMECP2\" \/>\n<meta property=\"article:published_time\" content=\"2023-12-16T21:12:50+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2023-12-20T18:46:25+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/dupmecp2.eu\/wp-content\/uploads\/2023\/12\/Huidagene-Logo.png\" \/>\n\t<meta property=\"og:image:width\" content=\"318\" \/>\n\t<meta property=\"og:image:height\" content=\"112\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/png\" \/>\n<meta name=\"author\" content=\"Caroline\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Escrito por\" \/>\n\t<meta name=\"twitter:data1\" content=\"Caroline\" \/>\n\t<meta name=\"twitter:label2\" content=\"Tiempo de lectura\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutos\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\/\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\/\/dupmecp2.eu\/huidagene-une-technologie-crispr-cas13-prometteuse-venue-de-chine-shanghai\/#article\",\"isPartOf\":{\"@id\":\"https:\/\/dupmecp2.eu\/huidagene-une-technologie-crispr-cas13-prometteuse-venue-de-chine-shanghai\/\"},\"author\":{\"name\":\"Caroline\",\"@id\":\"https:\/\/dupmecp2.eu\/#\/schema\/person\/b41e8cbba153cd974ee340386af279ee\"},\"headline\":\"Huidagene : Une technologie CRISPR-CAS13 prometteuse venue de Chine (Shanghai)\",\"datePublished\":\"2023-12-16T21:12:50+00:00\",\"dateModified\":\"2023-12-20T18:46:25+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\/\/dupmecp2.eu\/huidagene-une-technologie-crispr-cas13-prometteuse-venue-de-chine-shanghai\/\"},\"wordCount\":400,\"commentCount\":0,\"publisher\":{\"@id\":\"https:\/\/dupmecp2.eu\/#organization\"},\"image\":{\"@id\":\"https:\/\/dupmecp2.eu\/huidagene-une-technologie-crispr-cas13-prometteuse-venue-de-chine-shanghai\/#primaryimage\"},\"thumbnailUrl\":\"https:\/\/dupmecp2.eu\/wp-content\/uploads\/2023\/12\/Huidagene-Logo.png\",\"articleSection\":[\"Actualit\u00e9\"],\"inLanguage\":\"es\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\/\/dupmecp2.eu\/huidagene-une-technologie-crispr-cas13-prometteuse-venue-de-chine-shanghai\/#respond\"]}]},{\"@type\":\"WebPage\",\"@id\":\"https:\/\/dupmecp2.eu\/huidagene-une-technologie-crispr-cas13-prometteuse-venue-de-chine-shanghai\/\",\"url\":\"https:\/\/dupmecp2.eu\/huidagene-une-technologie-crispr-cas13-prometteuse-venue-de-chine-shanghai\/\",\"name\":\"Huidagene : Une technologie CRISPR-CAS13 prometteuse venue de Chine (Shanghai) - DupMECP2\",\"isPartOf\":{\"@id\":\"https:\/\/dupmecp2.eu\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\/\/dupmecp2.eu\/huidagene-une-technologie-crispr-cas13-prometteuse-venue-de-chine-shanghai\/#primaryimage\"},\"image\":{\"@id\":\"https:\/\/dupmecp2.eu\/huidagene-une-technologie-crispr-cas13-prometteuse-venue-de-chine-shanghai\/#primaryimage\"},\"thumbnailUrl\":\"https:\/\/dupmecp2.eu\/wp-content\/uploads\/2023\/12\/Huidagene-Logo.png\",\"datePublished\":\"2023-12-16T21:12:50+00:00\",\"dateModified\":\"2023-12-20T18:46:25+00:00\",\"description\":\"Une nouvelle perspective potentielle pour le traitement du syndrome de duplication MECP2 avec le CRIPSR-Cas13 de Huidagene. Le candidat-m\u00e9dicament HG204 a d\u00e9montr\u00e9 une r\u00e9duction significative de la prot\u00e9ine MeCP2 et la r\u00e9versibilit\u00e9 des sympt\u00f4mes.\",\"breadcrumb\":{\"@id\":\"https:\/\/dupmecp2.eu\/huidagene-une-technologie-crispr-cas13-prometteuse-venue-de-chine-shanghai\/#breadcrumb\"},\"inLanguage\":\"es\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\/\/dupmecp2.eu\/huidagene-une-technologie-crispr-cas13-prometteuse-venue-de-chine-shanghai\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"es\",\"@id\":\"https:\/\/dupmecp2.eu\/huidagene-une-technologie-crispr-cas13-prometteuse-venue-de-chine-shanghai\/#primaryimage\",\"url\":\"https:\/\/dupmecp2.eu\/wp-content\/uploads\/2023\/12\/Huidagene-Logo.png\",\"contentUrl\":\"https:\/\/dupmecp2.eu\/wp-content\/uploads\/2023\/12\/Huidagene-Logo.png\",\"width\":318,\"height\":112},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\/\/dupmecp2.eu\/huidagene-une-technologie-crispr-cas13-prometteuse-venue-de-chine-shanghai\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Accueil\",\"item\":\"https:\/\/dupmecp2.eu\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Actualit\u00e9\",\"item\":\"https:\/\/dupmecp2.eu\/category\/actualite\/\"},{\"@type\":\"ListItem\",\"position\":3,\"name\":\"Huidagene : Une technologie CRISPR-CAS13 prometteuse venue de Chine (Shanghai)\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\/\/dupmecp2.eu\/#website\",\"url\":\"https:\/\/dupmecp2.eu\/\",\"name\":\"DupMECP2\",\"description\":\"EU\",\"publisher\":{\"@id\":\"https:\/\/dupmecp2.eu\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\/\/dupmecp2.eu\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"es\"},{\"@type\":\"Organization\",\"@id\":\"https:\/\/dupmecp2.eu\/#organization\",\"name\":\"DupMECP2\",\"url\":\"https:\/\/dupmecp2.eu\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"es\",\"@id\":\"https:\/\/dupmecp2.eu\/#\/schema\/logo\/image\/\",\"url\":\"\",\"contentUrl\":\"\",\"caption\":\"DupMECP2\"},\"image\":{\"@id\":\"https:\/\/dupmecp2.eu\/#\/schema\/logo\/image\/\"}},{\"@type\":\"Person\",\"@id\":\"https:\/\/dupmecp2.eu\/#\/schema\/person\/b41e8cbba153cd974ee340386af279ee\",\"name\":\"Caroline\",\"sameAs\":[\"https:\/\/dupmecp2.eu\"],\"url\":\"https:\/\/dupmecp2.eu\/es\/author\/417a2385dc37aa45\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Huidagene: una prometedora tecnolog\u00eda CRISPR-CAS13 de China (Shanghai) - DupMECP2","description":"Una nueva perspectiva potencial para el tratamiento del s\u00edndrome de duplicaci\u00f3n MECP2 con CRIPSR-Cas13 de Huidagene. El candidato a f\u00e1rmaco HG204 demostr\u00f3 una reducci\u00f3n significativa de la prote\u00edna MeCP2 y reversibilidad de los s\u00edntomas.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/dupmecp2.eu\/es\/huidagene-una-prometedora-tecnologia-crispr-cas13-de-china-shanghai\/","og_locale":"es_ES","og_type":"article","og_title":"Huidagene : Une technologie CRISPR-CAS13 prometteuse venue de Chine (Shanghai) - DupMECP2","og_description":"Une nouvelle perspective potentielle pour le traitement du syndrome de duplication MECP2 avec le CRIPSR-Cas13 de Huidagene. Le candidat-m\u00e9dicament HG204 a d\u00e9montr\u00e9 une r\u00e9duction significative de la prot\u00e9ine MeCP2 et la r\u00e9versibilit\u00e9 des sympt\u00f4mes.","og_url":"https:\/\/dupmecp2.eu\/es\/huidagene-una-prometedora-tecnologia-crispr-cas13-de-china-shanghai\/","og_site_name":"DupMECP2","article_published_time":"2023-12-16T21:12:50+00:00","article_modified_time":"2023-12-20T18:46:25+00:00","og_image":[{"width":318,"height":112,"url":"https:\/\/dupmecp2.eu\/wp-content\/uploads\/2023\/12\/Huidagene-Logo.png","type":"image\/png"}],"author":"Caroline","twitter_card":"summary_large_image","twitter_misc":{"Escrito por":"Caroline","Tiempo de lectura":"2 minutos"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/dupmecp2.eu\/huidagene-une-technologie-crispr-cas13-prometteuse-venue-de-chine-shanghai\/#article","isPartOf":{"@id":"https:\/\/dupmecp2.eu\/huidagene-une-technologie-crispr-cas13-prometteuse-venue-de-chine-shanghai\/"},"author":{"name":"Caroline","@id":"https:\/\/dupmecp2.eu\/#\/schema\/person\/b41e8cbba153cd974ee340386af279ee"},"headline":"Huidagene : Une technologie CRISPR-CAS13 prometteuse venue de Chine (Shanghai)","datePublished":"2023-12-16T21:12:50+00:00","dateModified":"2023-12-20T18:46:25+00:00","mainEntityOfPage":{"@id":"https:\/\/dupmecp2.eu\/huidagene-une-technologie-crispr-cas13-prometteuse-venue-de-chine-shanghai\/"},"wordCount":400,"commentCount":0,"publisher":{"@id":"https:\/\/dupmecp2.eu\/#organization"},"image":{"@id":"https:\/\/dupmecp2.eu\/huidagene-une-technologie-crispr-cas13-prometteuse-venue-de-chine-shanghai\/#primaryimage"},"thumbnailUrl":"https:\/\/dupmecp2.eu\/wp-content\/uploads\/2023\/12\/Huidagene-Logo.png","articleSection":["Actualit\u00e9"],"inLanguage":"es","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/dupmecp2.eu\/huidagene-une-technologie-crispr-cas13-prometteuse-venue-de-chine-shanghai\/#respond"]}]},{"@type":"WebPage","@id":"https:\/\/dupmecp2.eu\/huidagene-une-technologie-crispr-cas13-prometteuse-venue-de-chine-shanghai\/","url":"https:\/\/dupmecp2.eu\/huidagene-une-technologie-crispr-cas13-prometteuse-venue-de-chine-shanghai\/","name":"Huidagene: una prometedora tecnolog\u00eda CRISPR-CAS13 de China (Shanghai) - DupMECP2","isPartOf":{"@id":"https:\/\/dupmecp2.eu\/#website"},"primaryImageOfPage":{"@id":"https:\/\/dupmecp2.eu\/huidagene-une-technologie-crispr-cas13-prometteuse-venue-de-chine-shanghai\/#primaryimage"},"image":{"@id":"https:\/\/dupmecp2.eu\/huidagene-une-technologie-crispr-cas13-prometteuse-venue-de-chine-shanghai\/#primaryimage"},"thumbnailUrl":"https:\/\/dupmecp2.eu\/wp-content\/uploads\/2023\/12\/Huidagene-Logo.png","datePublished":"2023-12-16T21:12:50+00:00","dateModified":"2023-12-20T18:46:25+00:00","description":"Una nueva perspectiva potencial para el tratamiento del s\u00edndrome de duplicaci\u00f3n MECP2 con CRIPSR-Cas13 de Huidagene. El candidato a f\u00e1rmaco HG204 demostr\u00f3 una reducci\u00f3n significativa de la prote\u00edna MeCP2 y reversibilidad de los s\u00edntomas.","breadcrumb":{"@id":"https:\/\/dupmecp2.eu\/huidagene-une-technologie-crispr-cas13-prometteuse-venue-de-chine-shanghai\/#breadcrumb"},"inLanguage":"es","potentialAction":[{"@type":"ReadAction","target":["https:\/\/dupmecp2.eu\/huidagene-une-technologie-crispr-cas13-prometteuse-venue-de-chine-shanghai\/"]}]},{"@type":"ImageObject","inLanguage":"es","@id":"https:\/\/dupmecp2.eu\/huidagene-une-technologie-crispr-cas13-prometteuse-venue-de-chine-shanghai\/#primaryimage","url":"https:\/\/dupmecp2.eu\/wp-content\/uploads\/2023\/12\/Huidagene-Logo.png","contentUrl":"https:\/\/dupmecp2.eu\/wp-content\/uploads\/2023\/12\/Huidagene-Logo.png","width":318,"height":112},{"@type":"BreadcrumbList","@id":"https:\/\/dupmecp2.eu\/huidagene-une-technologie-crispr-cas13-prometteuse-venue-de-chine-shanghai\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Accueil","item":"https:\/\/dupmecp2.eu\/"},{"@type":"ListItem","position":2,"name":"Actualit\u00e9","item":"https:\/\/dupmecp2.eu\/category\/actualite\/"},{"@type":"ListItem","position":3,"name":"Huidagene : Une technologie CRISPR-CAS13 prometteuse venue de Chine (Shanghai)"}]},{"@type":"WebSite","@id":"https:\/\/dupmecp2.eu\/#website","url":"https:\/\/dupmecp2.eu\/","name":"DupMECP2","description":"UE","publisher":{"@id":"https:\/\/dupmecp2.eu\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/dupmecp2.eu\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"es"},{"@type":"Organization","@id":"https:\/\/dupmecp2.eu\/#organization","name":"DupMECP2","url":"https:\/\/dupmecp2.eu\/","logo":{"@type":"ImageObject","inLanguage":"es","@id":"https:\/\/dupmecp2.eu\/#\/schema\/logo\/image\/","url":"","contentUrl":"","caption":"DupMECP2"},"image":{"@id":"https:\/\/dupmecp2.eu\/#\/schema\/logo\/image\/"}},{"@type":"Person","@id":"https:\/\/dupmecp2.eu\/#\/schema\/person\/b41e8cbba153cd974ee340386af279ee","name":"Caroline","sameAs":["https:\/\/dupmecp2.eu"],"url":"https:\/\/dupmecp2.eu\/es\/author\/417a2385dc37aa45\/"}]}},"_links":{"self":[{"href":"https:\/\/dupmecp2.eu\/es\/wp-json\/wp\/v2\/posts\/22177","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/dupmecp2.eu\/es\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/dupmecp2.eu\/es\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/dupmecp2.eu\/es\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/dupmecp2.eu\/es\/wp-json\/wp\/v2\/comments?post=22177"}],"version-history":[{"count":0,"href":"https:\/\/dupmecp2.eu\/es\/wp-json\/wp\/v2\/posts\/22177\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/dupmecp2.eu\/es\/wp-json\/wp\/v2\/media\/22151"}],"wp:attachment":[{"href":"https:\/\/dupmecp2.eu\/es\/wp-json\/wp\/v2\/media?parent=22177"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/dupmecp2.eu\/es\/wp-json\/wp\/v2\/categories?post=22177"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/dupmecp2.eu\/es\/wp-json\/wp\/v2\/tags?post=22177"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}